B. Braun Melsungen AG
Melsungen, Germany
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: B. Braun Melsungen AG
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Melsungen, Germany
- Modalities
- Sterile Injectables (vials, ampules, syringes), Infusion Solutions, Irrigation Solutions, Volume Replacement Solutions, Parenteral Nutrition, Anesthetics, Dermatological Products (creams, gels, pomades), Medical Device Contract Manufacturing, Clinical Trial Supply, Procedure Packs
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About B. Braun Melsungen AG
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSterile Injectables (vials, ampules, syringes), Infusion Solutions, Irrigation Solutions, Volume Replacement Solutions, Parenteral Nutrition, Anesthetics, Dermatological Products (creams, gels, pomades), Medical Device Contract Manufacturing, Clinical Trial Supply, Procedure Packs
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (10 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (10 modalities)
Recent News 10 articles
Inguinal Hernia Market Size to Reach CAGR of 5.22% during 2024-2034, Impelled by Effective Medical Interventions - BioSpace
Advanced Wound Care Market Size Anticipated to Grow with a Substantial CAGR of 10.51% and Extend to USD 16.97 Billion During the Study Period 2018-26, Examines DelveInsight - PR Newswire
Tissue Nanotransfection Market Size to Hit USD 15.25 Billion by 2035 - Precedence Research
Global $314 Billion Healthcare Contract Development & Manufacturing Organization (CDMO) Market to 2026 - PR Newswire
Top 5 Vendors in the Absorbable Sutures Market From 2019 to 2023 | Technavio - BioSpace
Autologous Matrix-induced Chondrogenesis Market Segments - openPR.com
Knee Cartilage Repair Market Size, Share, Forecast to 2034 - Fortune Business Insights
A proof of concept study for the differentiation of SARS-CoV-2, hCoV-NL63, and IAV-H1N1 in vitro cultures using ion mobility spectrometry - Nature
Sterile Spin-Lock Connectors Market to Reach 245 Index by 2035 on Single-Use Bioreactor Expansion - IndexBox
Degenerative Disc Disease Treatment Market Size Report, 2032 - Global Market Insights Inc.
Frequently Asked Questions About B. Braun Melsungen AG
What is B. Braun Melsungen AG's CDMO Signal Score?
B. Braun Melsungen AG has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating B. Braun Melsungen AG for a manufacturing program?
Use the free AI matchmaker to compare B. Braun Melsungen AG against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.